000			01458 a2200409 4500
005			20250512200025.0
264		0	_c19830909
008			198309s 0 0 eng d
022			_a0277-0008
024	7		_a10.1002/j.1875-9114.1983.tb03245.x _2doi
040			_aNLM _beng _cNLM
100	1		_aSack, D M
245	0	0	_aDrug therapy of inflammatory bowel disease. _h[electronic resource]
260			_bPharmacotherapy _c
300			_a158-76 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Review
650	0	4	_aAdjuvants, Immunologic _xtherapeutic use
650	0	4	_aAdrenal Cortex Hormones _xtherapeutic use
650	0	4	_aAdult
650	0	4	_aAnti-Bacterial Agents _xtherapeutic use
650	0	4	_aAntidiarrheals _xtherapeutic use
650	0	4	_aChild
650	0	4	_aCholestyramine Resin _xtherapeutic use
650	0	4	_aClinical Trials as Topic
650	0	4	_aColitis, Ulcerative _xdrug therapy
650	0	4	_aCrohn Disease _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aMast Cells _xdrug effects
650	0	4	_aMetronidazole _xtherapeutic use
650	0	4	_aPremedication
650	0	4	_aProctitis _xdrug therapy
650	0	4	_aSulfasalazine _xadverse effects
700	1		_aPeppercorn, M A
773	0		_tPharmacotherapy _gvol. 3 _gno. 3 _gp. 158-76
856	4	0	_uhttps://doi.org/10.1002/j.1875-9114.1983.tb03245.x _zAvailable from publisher's website
999			_c6136118 _d6136118